Le SHU peut-il causer des problèmes à long terme ?
Oui, certains patients peuvent développer des complications rénales ou neurologiques à long terme.
Problèmes à long termeComplications rénalesComplications neurologiques
#3
Comment le SHU affecte-t-il le système nerveux ?
Il peut provoquer des convulsions, des AVC ou des troubles de la conscience chez certains patients.
Système nerveuxConvulsionsAVC
#4
Le SHU peut-il entraîner des décès ?
Dans de rares cas, le SHU peut être fatal, surtout en cas de complications graves.
DécèsComplications gravesSyndrome hémolytique et urémique
#5
Quelles sont les conséquences sur la qualité de vie ?
Les complications peuvent affecter la qualité de vie, nécessitant un suivi médical régulier.
Qualité de vieSuivi médicalComplications
Facteurs de risque
5
#1
Quels sont les facteurs de risque du SHU ?
Les facteurs incluent l'infection par E. coli, l'âge jeune et des antécédents de maladies rénales.
Facteurs de risqueInfection par E. coliMaladies rénales
#2
Les enfants sont-ils plus à risque de SHU ?
Oui, les enfants, en particulier ceux de moins de 5 ans, sont plus susceptibles de développer le SHU.
EnfantsSyndrome hémolytique et urémiqueFacteurs de risque
#3
Les personnes âgées sont-elles à risque ?
Oui, les personnes âgées peuvent également être à risque, surtout en cas de comorbidités.
Personnes âgéesComorbiditésFacteurs de risque
#4
Les antécédents familiaux influencent-ils le risque ?
Des antécédents familiaux de maladies rénales peuvent augmenter le risque de SHU.
Antécédents familiauxMaladies rénalesFacteurs de risque
#5
Le contact avec des animaux augmente-t-il le risque ?
Oui, le contact avec des animaux, en particulier les bovins, peut augmenter le risque d'infection.
Contact avec des animauxInfectionFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Syndrome hémolytique et urémique : Questions médicales les plus fréquentes",
"headline": "Syndrome hémolytique et urémique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Syndrome hémolytique et urémique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-29",
"dateModified": "2026-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Syndrome hémolytique et urémique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Microangiopathies thrombotiques",
"url": "https://questionsmedicales.fr/mesh/D057049",
"about": {
"@type": "MedicalCondition",
"name": "Microangiopathies thrombotiques",
"code": {
"@type": "MedicalCode",
"code": "D057049",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.140.855.925"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Syndrome hémolytique et urémique atypique",
"alternateName": "Atypical Hemolytic Uremic Syndrome",
"url": "https://questionsmedicales.fr/mesh/D065766",
"about": {
"@type": "MedicalCondition",
"name": "Syndrome hémolytique et urémique atypique",
"code": {
"@type": "MedicalCode",
"code": "D065766",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.140.855.925.500.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Syndrome hémolytique et urémique",
"alternateName": "Hemolytic-Uremic Syndrome",
"code": {
"@type": "MedicalCode",
"code": "D006463",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Arvind Bagga",
"url": "https://questionsmedicales.fr/author/Arvind%20Bagga",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India."
}
},
{
"@type": "Person",
"name": "Olivia Boyer",
"url": "https://questionsmedicales.fr/author/Olivia%20Boyer",
"affiliation": {
"@type": "Organization",
"name": "Pediatric Nephrology, Necker Enfants Malades Hospital, Université Paris Cité, France; Néphrologie Pédiatrique, Hôpital Necker, 149 Rue de Sèvres, Paris 75015, France."
}
},
{
"@type": "Person",
"name": "Rupesh Raina",
"url": "https://questionsmedicales.fr/author/Rupesh%20Raina",
"affiliation": {
"@type": "Organization",
"name": "Akron Nephrology Associates/Cleveland Clinic Akron General Medical Center, Akron, OH 44307, USA."
}
},
{
"@type": "Person",
"name": "Priyanka Khandelwal",
"url": "https://questionsmedicales.fr/author/Priyanka%20Khandelwal",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Duration of prodromal phase and severity of hemolytic uremic syndrome.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37526769",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00467-023-06104-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cerebral microstructural changes in children suffering from hemolytic uremic syndrome.",
"datePublished": "2023-08-10",
"url": "https://questionsmedicales.fr/article/37558834",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00431-023-05130-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomes.",
"datePublished": "2023-06-12",
"url": "https://questionsmedicales.fr/article/37306721",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00467-023-06037-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.",
"datePublished": "2023-12-06",
"url": "https://questionsmedicales.fr/article/38057431",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00467-023-06216-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pearls & Oy-sters: Neurologic Involvement in Shiga Toxin-Associated Hemolytic Uremic Syndrome.",
"datePublished": "2024-10-08",
"url": "https://questionsmedicales.fr/article/39378389",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/WNL.0000000000209881"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Hémopathies et maladies lymphatiques",
"item": "https://questionsmedicales.fr/mesh/D006425"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hémopathies",
"item": "https://questionsmedicales.fr/mesh/D006402"
},
{
"@type": "ListItem",
"position": 4,
"name": "Anomalies des plaquettes",
"item": "https://questionsmedicales.fr/mesh/D001791"
},
{
"@type": "ListItem",
"position": 5,
"name": "Thrombopénie",
"item": "https://questionsmedicales.fr/mesh/D013921"
},
{
"@type": "ListItem",
"position": 6,
"name": "Microangiopathies thrombotiques",
"item": "https://questionsmedicales.fr/mesh/D057049"
},
{
"@type": "ListItem",
"position": 7,
"name": "Syndrome hémolytique et urémique",
"item": "https://questionsmedicales.fr/mesh/D006463"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Syndrome hémolytique et urémique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Syndrome hémolytique et urémique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Syndrome hémolytique et urémique",
"description": "Comment diagnostique-t-on le SHU ?\nQuels tests sont utilisés pour le SHU ?\nQuels signes indiquent un SHU ?\nLe SHU peut-il être confondu avec d'autres maladies ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D006463#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Syndrome hémolytique et urémique",
"description": "Quels sont les symptômes principaux du SHU ?\nLe SHU provoque-t-il des douleurs ?\nComment se manifeste l'insuffisance rénale dans le SHU ?\nLe SHU peut-il entraîner des complications neurologiques ?\nY a-t-il des signes cutanés associés au SHU ?",
"url": "https://questionsmedicales.fr/mesh/D006463#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Syndrome hémolytique et urémique",
"description": "Comment prévenir le SHU ?\nLes vaccins peuvent-ils prévenir le SHU ?\nQuelles sont les mesures d'hygiène recommandées ?\nLe SHU peut-il être évité après une infection ?\nLes personnes à risque doivent-elles être surveillées ?",
"url": "https://questionsmedicales.fr/mesh/D006463#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Syndrome hémolytique et urémique",
"description": "Quel est le traitement principal du SHU ?\nDes antibiotiques sont-ils utilisés pour le SHU ?\nQuand la transfusion sanguine est-elle nécessaire ?\nLe traitement est-il différent pour les enfants ?\nLe SHU nécessite-t-il une hospitalisation ?",
"url": "https://questionsmedicales.fr/mesh/D006463#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Syndrome hémolytique et urémique",
"description": "Quelles complications peuvent survenir avec le SHU ?\nLe SHU peut-il causer des problèmes à long terme ?\nComment le SHU affecte-t-il le système nerveux ?\nLe SHU peut-il entraîner des décès ?\nQuelles sont les conséquences sur la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D006463#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Syndrome hémolytique et urémique",
"description": "Quels sont les facteurs de risque du SHU ?\nLes enfants sont-ils plus à risque de SHU ?\nLes personnes âgées sont-elles à risque ?\nLes antécédents familiaux influencent-ils le risque ?\nLe contact avec des animaux augmente-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006463#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on le SHU ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines, des tests de fonction rénale et des antécédents cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le SHU ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins, des analyses d'urine et parfois une biopsie rénale sont effectués."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un SHU ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent fatigue, pâleur, ecchymoses et diminution de la production d'urine."
}
},
{
"@type": "Question",
"name": "Le SHU peut-il être confondu avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec d'autres syndromes hématologiques ou rénaux."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique médical aide à identifier des infections récentes ou des expositions à des toxines."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux du SHU ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée sanglante, douleurs abdominales, fatigue et œdème."
}
},
{
"@type": "Question",
"name": "Le SHU provoque-t-il des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs abdominales et des douleurs musculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'insuffisance rénale dans le SHU ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle se manifeste par une diminution de la production d'urine et une élévation des déchets sanguins."
}
},
{
"@type": "Question",
"name": "Le SHU peut-il entraîner des complications neurologiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des convulsions ou des troubles de la conscience peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés au SHU ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées ou des ecchymoses peuvent apparaître en raison de la thrombocytopénie."
}
},
{
"@type": "Question",
"name": "Comment prévenir le SHU ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une bonne hygiène alimentaire et la cuisson adéquate des aliments."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils prévenir le SHU ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin spécifique contre le SHU."
}
},
{
"@type": "Question",
"name": "Quelles sont les mesures d'hygiène recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains fréquemment et éviter les aliments crus ou mal cuits sont essentiels."
}
},
{
"@type": "Question",
"name": "Le SHU peut-il être évité après une infection ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'est pas toujours possible d'éviter le SHU après une infection, mais une surveillance est cruciale."
}
},
{
"@type": "Question",
"name": "Les personnes à risque doivent-elles être surveillées ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes à risque, comme celles ayant des antécédents d'infections, doivent être surveillées."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal du SHU ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est le soutien rénal, souvent par dialyse, et la gestion des symptômes."
}
},
{
"@type": "Question",
"name": "Des antibiotiques sont-ils utilisés pour le SHU ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques ne sont pas recommandés car ils peuvent aggraver la maladie dans certains cas."
}
},
{
"@type": "Question",
"name": "Quand la transfusion sanguine est-elle nécessaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La transfusion peut être nécessaire en cas d'anémie sévère ou de thrombocytopénie importante."
}
},
{
"@type": "Question",
"name": "Le traitement est-il différent pour les enfants ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement peut varier, notamment en raison de la gravité et des causes sous-jacentes."
}
},
{
"@type": "Question",
"name": "Le SHU nécessite-t-il une hospitalisation ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hospitalisation est souvent nécessaire pour surveiller et traiter les complications."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le SHU ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance rénale chronique, les troubles neurologiques et les problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Le SHU peut-il causer des problèmes à long terme ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent développer des complications rénales ou neurologiques à long terme."
}
},
{
"@type": "Question",
"name": "Comment le SHU affecte-t-il le système nerveux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer des convulsions, des AVC ou des troubles de la conscience chez certains patients."
}
},
{
"@type": "Question",
"name": "Le SHU peut-il entraîner des décès ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans de rares cas, le SHU peut être fatal, surtout en cas de complications graves."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences sur la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent affecter la qualité de vie, nécessitant un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du SHU ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'infection par E. coli, l'âge jeune et des antécédents de maladies rénales."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque de SHU ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants, en particulier ceux de moins de 5 ans, sont plus susceptibles de développer le SHU."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent également être à risque, surtout en cas de comorbidités."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux de maladies rénales peuvent augmenter le risque de SHU."
}
},
{
"@type": "Question",
"name": "Le contact avec des animaux augmente-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le contact avec des animaux, en particulier les bovins, peut augmenter le risque d'infection."
}
}
]
}
]
}
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
2018-10-29
Pediatric Nephrology, Necker Enfants Malades Hospital, Université Paris Cité, France; Néphrologie Pédiatrique, Hôpital Necker, 149 Rue de Sèvres, Paris 75015, France.
Publications dans "Syndrome hémolytique et urémique" :
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
2018-10-29
Nephrogenetics Laboratory, Department of Pediatrics, Hacettepe University School of Medicine, Ankara, Turkey;Division of Pediatric Nephrology, Department of Pediatrics, Hacettepe University School of Medicine, Ankara, Turkey.
Publications dans "Syndrome hémolytique et urémique" :
Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, 3347 Forbes Avenue Suite 220, Pittsburgh, PA 15213, USA; The CRISMA (Clinical Research, Investigation and Systems Modeling of Acute Illness) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, 3550 Terrace Street, Scaife Hall, Suite 600, Pittsburgh, PA 15213, USA; Department of Nephrology, Children's Hospital of Pittsburgh of UPMC, 4401 Penn Avenue, Floor 3, Pittsburgh, PA 15224, USA.
Publications dans "Syndrome hémolytique et urémique" :
Some data have recognized an association between shorter prodromal phase and severe episode of Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome (STEC-HUS). Our aims were to con...
Patients treated from 2000 to 2022 were compared according to the presence of severe (> 10 days of dialysis and/or extra-renal complications) or non-severe disease. Association between prodromal phase...
Non-severe (n = 145) and severe (n = 71) cases were compared. The latter had shorter prodromal phase, higher leukocyte count, hemoglobin, lactic dehydrogenase, liver enzymes, C-reactive protein, urea ...
This study found that duration of prodromal phase is an independent predictor of complicated STEC-HUS and confirms that shorter prodromal phase is associated with worse prognosis. A higher resolution ...
To evaluate microstructural cerebral changes in children suffering from typical hemolytic uremic syndrome (HUS) based on apparent diffusion coefficient (ADC) maps. For 12 pediatric HUS patients (0.8 -...
Streptococcus pneumoniae-associated hemolytic uremic syndrome (P-HUS) is a rare and severe disease. Only a few reports have been published about eculizumab use in P-HUS....
We analyzed demographic, clinical, and laboratory data of patients with P-HUS from our center....
The cohort consisted of 4 females and 3 males. All patients had pneumonia. Four were given eculizumab (days 1-3). The eculizumab group required a shorter duration of dialysis and mechanical ventilatio...
Despite the fact that the eculizumab group showed better outcomes, eculizumab does not seem to improve the course of P-HUS compared with previous reports. Kidney outcomes are strongly correlated with ...
Infection-associated hemolytic uremic syndrome (IA-HUS), most often due to infection with Shiga toxin-producing bacteria, mainly affects young children. It can be acutely life-threatening, as well as ...
PubMed, Embase, and Web of Science were systematically searched for studies reporting the impact of eculizumab on medium- to long-term outcomes in IA-HUS. The final search occurred on March 2, 2022. S...
A total of 2944 studies were identified. Of these, 14 studies including 386 eculizumab-treated patients met inclusion criteria. All studies were observational. Shiga toxin-producing E. coli (STEC) was...
Current observational evidence does not permit any conclusion regarding the impact of eculizumab in IA-HUS given critical risk of bias. Results of randomized clinical trials are eagerly awaited, as ne...
OSF Registries, MSZY4, Registration DOI https://doi.org/10.17605/OSF.IO/MSZY4 ....
The gastrointestinal (GI) tract represents one of the main targets of typical hemolytic uremic syndrome (HUS) in children. In this observational study, we tried to establish (1) the main features of G...
A total of 79 STEC-HUS patients were admitted to our pediatric nephrology department between January 2012 and June 2021. Evidence of intestinal, hepatobiliary, and pancreatic involvements was reported...
Six patients developed a bowel complication: two developed rectal prolapse, and four developed bowel perforation which resulted in death for three of them and in bowel stenosis in one patient. Acute p...
During STEC-HUS, GI complications are common, ranging from self-limited elevation of laboratory markers to bowel perforation, a severe complication with a relevant impact on morbidity and mortality. H...
Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS) is associated with high morbidity and relevant mortality. Previous small studies showed that volume expansion could improve the cours...
Data of pediatric patients with STEC-HUS were analyzed retrospectively. Course and outcome of patients treated with volume expansion (VE) from 2019 to 2022 (n = 38) were compared to historical control...
Patients in the VE group had a significant relative median weight gain compared to HC (7.8% (3.4-11.3) vs. 1.2% (- 0.7-3.9), p < 0.0001) 48 h after admission. The need for dialysis was not reduced by ...
This study suggests that volume expansion may be associated with the mitigation of the acute course of STEC-HUS, especially severe neurological involvement and the development of CKD. Prospective tria...
The immune form of thrombotic thrombocytopenic purpura (iTTP) and the hemolytic and uremic syndrome (HUS) are two major forms of thrombotic microangiopathy (TMA). Their treatment has been recently gre...
The prevalence and predictors of cerebral lesions appearing during the acute phase of iTTP and Shiga toxin-producing Escherichia coli-HUS or atypical HUS were evaluated in a prospective multicenter st...
Univariate analysis was performed to report the main differences between patients with iTTP and those with HUS or between patients with acute cerebral lesions and the others. Multivariable logistic re...
Among 73 TMA cases (mean age 46.9 ± 16 years (range 21-87 years) with iTTP (n = 57) or HUS (n = 16), one-third presented with acute ischemic cerebral lesions on magnetic resonance imagery (MRI); two i...
At the acute phase of iTTP or HUS, both symptomatic and covert ischemic lesions are detected in one third of cases on MRI. Diagnosis of iTTP and the presence of old infarcts on MRI are associated with...
Shiga-toxin associated-hemolytic uremic syndrome (STEC-HUS) is a severe cause of acute kidney injury (AKI) in children. Although most children recover, about 5% die and 30% develop chronic renal morbi...
We describe a 12 y.o. (patient 1) and two 2 y.o. twins (patients 2 and 3) with STEC-HUS requiring continuous renal replacement therapy (CRRT) who were enrolled in two separate studies of the SCD....
Patient 1 presented with STEC-HUS causing AKI and multisystem organ failure and received 7 days of SCD and CRRT treatment. After SCD initiation, the patient had gradual recovery of multi-organ dysfunc...
Immunomodulatory treatment with the SCD was associated with improvements in multisystem stigmata of STEC-HUS-induced AKI and was well-tolerated without any device-related adverse events....
Hemolytic uremic syndrome (HUS) is a serious cause of acute kidney injury in children. There is a suggestion that coronavirus disease 2019 (COVID-19) may be a trigger for HUS. In this study, we presen...
A previously healthy 13-year-old girl with fever and vomiting was referred to our hospital. Laboratory investigations revealed direct Coombs-negative hemolytic anemia, thrombocytopenia and renal impai...
COVID-19 can be associated with HUS relapses, leading to chronic kidney disease. Further studies should investigate the mechanism of HUS associated with COVID-19....
